Web Site : http://www.chinamedicalsystem.com/

The Group was established in May 1995, and is a fully integrated, profitable pharmaceutical group focusing on research development, manufacturing and sales & marketing of pharmaceuticals. On 28 December 2006, China Medical System Holdings Limited was incorporated, becoming the current holding company of the Group. With 12 years of history in China, a strong own professional sales & marketing and R&D team was built. Currently, CMS has 5 products with sole distribution rights in the PRC, 3 in-house developed products and a range of medical equipment in marketing and 8 new drugs under development, ranging from pending Chinese drug authority's final approval, clinical test stages & early stage of R&D. CMS is one of the two foreign companies which have obtained China national drug distribution network license.

2

3

4

5

http://www.investegate.co.uk/Article.aspx?id=200804030701404966R


China Medical Systems Holdings Ltd
03 April 2008

China Medical System Holdings Limited
('CMS' or 'the Company')

Maiden Final Results For the year ended 31 December 2007

China Medical System Holdings Limited (AIM: CMSH), the profitable Chinese
pharmaceutical sales, marketing and research company, is pleased to announce its maiden final results for the year ended 31 December 2007.

Financial Highlights

Record sales of US$51.7 million up 38% (2006: US$37.6 million)

Gross Profit up 30% to US$33.6 million (2006: US$25.9 million)

Adjusted Net Profit(1) up 65% to US$11.4 million (2006: US$6.9 million)

Net Profit US$8.7 million up 123% (2006: US$3.9 million)

Adjusted Net Margin on Sales(2) of 22% (2006: 18%)

Cash and cash equivalents of US$17.6 million (2006: US$8.9 million)

Maiden final dividend of US$0.07 per share and special dividend of US$0.03 per share


(1) Adjusted Net Profit represents net profit excluding IPO expenses, Share
based payment expenses and Employee benefits recognized.

(2) Adjusted Net Margin on sales represents Adjusted Net Profit as a percentage of sales

Operational Highlights

Listed on the AIM market of the London Stock Exchange in June 2007 and
successfully raised a gross of 10 million

Introduced new drugs to the portfolio: Augentropfen Stulln Mono (eye drops),
GanFuLe Tablet and WeiMaiNing which have contributed US$6.1 million of sales
in 2007

Expanded sales network by recruiting over 100 new sales from university
graduates

Made progress in R&D program

Achieved double digit growth in sales of existing imported products

Acquired Boundless Horizon (Shan Dong) Medical Appliances Co. Ltd. and added
the Cardiac Monitoring System, a new medical device

Post Review Period

Exclusive and extendable three year agency and distribution agreement signed
in March 2008 with Tibet Rhodiola Pharmaceutical Holding Company for the
distribution of Nesiritide in China

Exclusive and extendable five year agency and distribution agreement signed in March 2008 with Bioniche Teoranta to distribute Cystistat in China (excluding Hong Kong)

Commenting on the final results, Mr Kong Lam, Chairman & CEO, said:

'CMS has made considerable progress since its successful flotation in June 2007
within both its distribution and trading business and R&D division. The Company
has again achieved record sales which are up by 38%. In line with the strategy
at the time of our IPO, we have added three new drugs to our exclusive
distribution portfolio which have already started contributing to the revenue.
In addition, a further two products have been licensed since the year end.

'We were also delighted to report significant progress within the R&D division
during the year, most notably the notice from the State Food and Drug
Administration (SFDA), which had previously halted communications on all
clinical trial notifications, requesting us to enlarge the patient sample group
in the clinical trial of our novel product CMS024 for the treatment of primary
liver cancer. We look forward to reporting on this trial in due course and aim
to file the New Drug Application within two years' time.'


Dividend Declaration

I am delighted to report that the Board is recommending a maiden final dividend
of US$0.07 per share and a special dividend of US$0.03 per share, making the
total proposed dividend of US$0.10 per share. The final and special dividends
equate to 35% and 15% of earnings per share for the year ended 31 December 2007
respectively. The Board considers that the final dividend is consistent with the intended dividend policy of the Company at a level of 25% to 50% of the net
profits for the year. The Board also recommends a special dividend to provide
shareholders with a favorable cash return. Subject to approval of shareholders
at the Annual General Meeting ('AGM'), the final and special dividends will be
paid on or about 8th May 2008 to shareholders on the register on 18th April
2008, with an ex-dividend date of 16th April 2008.

This is another one of those Chinese shares which offers good news but will not perform in its share price. AVOID.

Possibly.........time will tell whether its a raging buy or a potential short.

Well, directors are buying and the SP is nicely moving upwards all the time. I can handle that.

In from sub 110p and happy to hold.

China Medical System 3,5 (BUY) - Initiating coverage

CMSH.L 126.5p (Target price 193p) Market Cap: 59.8m

CMS benefits strongly from its distinctive business model and own sales force. We expect net profits to grow by at least 35% per annum in the next three years. We initiate coverage with a BUY recommendation and a target price of 193p.

Zhining Xu
Research Analyst
Seymour Pierce

http://www.investegate.co.uk/Article.aspx?id=200807250700037900Z

RNS Number : 7900Z
China Medical Systems Holdings Ltd
25 July 2008


TRADING UPDATE

China Medical System Holdings Ltd. (AIM: CMSH), the integrated and profitable Chinese pharmaceutical company is pleased to announce a trading update for the first six months ending 30 June 2008.

The Company is pleased to report that trading for the first half of 2008 was in line with market expectations, with half year revenues anticipated to be approximately US$33.8 million. This represents year on year growth of approximately 41%. Sales for the first 6 months of 2007 amounted to US$23.9 million.

Historically the second half of the year has been the stronger period of CMS's financial year. Moreover, with the addition of 2 new products to the portfolio in 2008, the Board anticipates that sales in the second half of 2008 will once more exceed those of the first half.

Mr Lam Kong, Chairman of China Medical System Holdings Ltd. said, 'CMS has continued to make great progress in boosting the sales of existing products and in-licensing new products to expand revenue source, and I am very pleased by the 41% growth in sales from last year.'

RNS Number : 3098A
China Medical Systems Holdings Ltd
31 July 2008


China Medical System has been approved to commence the Phase 2 clinical trial for a novel cancer treatment

China Medical System Holdings Ltd. (AIM: CMSH), the integrated and profitable Chinese pharmaceutical company is pleased to announce that it has received approval from the Chinese State Food and Drug Administration (SFDA) to commence the Phase II clinical trial for CMS024-02 (Tyroservatide), an in-house developed novel drug for the treatment of non-small cell lung cancer, one of the most common malignant tumours in China.

This marks a positive development for CMS024-02 following the submission of Phase II clinical trial application to SFDA in March 2007. The results of the Phase I clinical trial have demonstrated that CMS024-02 is safe and well tolerated by patients. The Company plans to initiate the Phase II Clinical Trial Protocol in the second half of 2008.

Mr Lam Kong, Chairman of China Medical System Holdings Ltd., said: 'We are very pleased with the approval of CMS024-02 for further clinical trial from SFDA. It is the second novel drug we have developed in house to Phase II trial. While our sales and marketing business is still growing, we are pleased that we have also made great progress in our R&D pipeline.'